NICE recommends Vitrakvi (larotrectinib) for use on Cancer Drugs Fund
Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after it was previously rejected.
List view / Grid view
Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after it was previously rejected.
The EMA has announced its approval for marketing authorisation in the EU for Vitrakvi (larotrectinib), used to treat solid tumours with a specific gene mutation.